Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 14;15(16):4087.
doi: 10.3390/cancers15164087.

IMP3 Expression as a Potential Tumour Marker in High-Risk Localisations of Cutaneous Squamous Cell Carcinoma: IMP3 in Metastatic cSCC

Maurice Klein  1 , Merle Wefers  2 , Christian Hallermann  3   4 , Henrike J Fischer  5 , Frank Hölzle  1 , Kai Wermker  6
Affiliations

IMP3 Expression as a Potential Tumour Marker in High-Risk Localisations of Cutaneous Squamous Cell Carcinoma: IMP3 in Metastatic cSCC

Maurice Klein et al. Cancers (Basel). .

Abstract

Background: High IMP3 expression is correlated with a worse outcome. Until now, there have been no data about IMP3 expression and clinical outcome for high-risk localisation of squamous cell carcinoma of the skin (cSCC).

Methods: One-hundred twenty-two patients with cSCC of the lip and ear were included, and IMP3 expression in the tumours was immunohistochemically assessed in different evaluation approaches. Subsequently, subgroups were analysed in a matched pair approach and correlated with clinical pathologic parameters. In the following, different IMP3 analysis methods were tested for clinical suitability.

Results: We found a significant correlation between IMP3 expression and risk for lymph node metastasis, local relapse, and progression-free survival.

Conclusions: On basis of our data, we suggest a prognostic benefit cutoff value for high (>50%) and low (<50%) IMP3 expression. Thus, IMP3 expression has a high scientific potential for further studies and could potentially be used as a prognostic marker in diagnostic and therapeutic decision-making.

Keywords: HNSCC; IMP3; ear cancer; lip cancer; skin cancer; squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(Left side) IMP3 expression correlates positively with nodal status (N+/N−) in high-risk localisation of squamous cell carcinoma of the ear (ECSCC) and lip (LSCC) (p < 0.001). (Right side) The subgroups analysis of LSCC N+/N− and ECSCC N+/N− and IMP3 expression show each a significant correlation with nodal status (p < 0.001). *** p < 0.001.
Figure 2
Figure 2
The progression-free survival was shortened depending on the IMP3 expression ranges (IMP3 Analysis Category I; <25%, 25–50%, 50–75%, >75%). A higher IMP3 expression of >50% was correlated with a less progression-free survival.
Figure 3
Figure 3
The disease-specific survival tended to be reduced (p = 0.092) from an IMP3 expression of >50% (IMP3 Analysis Category II).
Figure 4
Figure 4
The IMP3 expression range >50%, <50% (IMP3 Analysis Category II) showed a significantly (p < 0.001) reduced progression-free survival with an IMP3 expression of >50%.
See this image and copyright information in PMC

References

    1. Leiter U., Heppt M.V., Steeb T., Amaral T., Bauer A., Becker J.C., Breitbart E., Breuninger H., Diepgen T., Dirschka T., et al. S3 Guideline for Actinic Keratosis and Cutaneous Squamous Cell Carcinoma (CSCC)—Short Version, Part 2: Epidemiology, Surgical and Systemic Treatment of CSCC, Follow-up, Prevention and Occupational Disease. J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG. 2020;18:400–413. doi: 10.1111/ddg.14072. - DOI - PubMed
    1. Alam M., Ratner D. Cutaneous Squamous-Cell Carcinoma. N. Engl. J. Med. 2001;344:975–983. doi: 10.1056/NEJM200103293441306. - DOI - PubMed
    1. Bota J.P., Lyons A.B., Carroll B.T. Squamous Cell Carcinoma of the Lip-A Review of Squamous Cell Carcinogenesis of the Mucosal and Cutaneous Junction. Dermatol. Surg. 2017;43:494–506. doi: 10.1097/DSS.0000000000001020. - DOI - PubMed
    1. Breuninger H., Bootz F., Hauschild A., Kortmann R.-D., Wolff K., Stockfleth E., Szeimies M., Rompel R., Garbe C. Short German Guidelines: Squamous Cell Carcinoma. JDDG J. Dtsch. Dermatol. Ges. 2008;6:S5–S8. doi: 10.1111/j.1610-0387.2008.06706.x. - DOI - PubMed
    1. Schmults C.D., Karia P.S., Carter J.B., Han J., Qureshi A.A. Factors Predictive of Recurrence and Death from Cutaneous Squamous Cell Carcinoma: A 10-Year, Single-Institution Cohort Study. JAMA Dermatol. 2013;149:541. doi: 10.1001/jamadermatol.2013.2139. - DOI - PubMed

LinkOut - more resources